|INSIGHT||* This study has finished *|
|Full title:||Investigating Strategies to Improve Clinical Trial Opportunities in Oncology in New Zealand|
|Cancer type:||Gynaecological cancers, other|
|Substantial gains have been made in our understanding of the underlying pathogenesis of cancer but to date these have not been matched with improvements in cure. Cancer remains the leading cause of mortality in New Zealand and is likely to be the defining health issue for the next decade. Clinical trials are designed to improve patient outcomes with the ultimate global priority to reduce cancer related morbidity and mortality. Importantly, they offer access to new therapies and have been shown to impact patient outcomes. Despite the recognition of their importance, less than 5% of adult patients with cancer are involved in clinical trials.
Multiple barriers to enrolment in clinical trials have been recognised including patient, clinician and institutional factors. There is significant geographical heterogeneity with trial access and recruitment which extends beyond the developing and developed world. Costs with respect to time and resource have important ramifications. To improve trial enrolment it is critical to understand the barriers relevant to our patient population. This project is designed to investigate clinician, institution and importantly patient factors across New Zealand and develop strategies to help address them.
The objectives of this study are:
|Lead Investigator:||Dr Michelle Wilson|
|Contact:||Sarah Benge (email@example.com)|
|Sponsor:||University of Auckland|
|Funder:||Goldman Sachs award|
|Trial Registry reference:||Nil|